Table 2
Open in new tab

Patient data during follow-up (see also text)

LV-DCM pts number (sex)Further diagnoses ROSS/NYHA FC (I–IV)BW (kg) (percentile)Age (mo)HR (/min) at restLV-EDD (mm) z-scoreLV-EF (%)RPA/LPA MVP-7 or -9 dP (mmHG)Anti-cong. Anti. aggreg. therapy B-L-S + ASA, CRemarks in term of FU
1. (f)Improved, FR,
FC-I		20
(98)		428740
(+1.4)		48MVP-9/-9
30/45		B-L-S + ASA + C
++		RPA-PFR
exchange
4 mo. after ePAB
2. (f)Improved
FR
FC-I		6.5
(55)		711227
(+1.5)		57MVP-9/-7
30/32		B-L-S + ASA + C6 mo FU Infect/RPA thrombus?
RPA-PFR
partial-de-banding
3. (m)Improved
FR
FC-I		4.5
(30)		411824
(+1.5)		55MVP-7/-7
32/36		B-L-S + ASA + CBarth-S.
related intermittent
diarrhea
LV-DCM pts number (sex)Further diagnoses ROSS/NYHA FC (I–IV)BW (kg) (percentile)Age (mo)HR (/min) at restLV-EDD (mm) z-scoreLV-EF (%)RPA/LPA MVP-7 or -9 dP (mmHG)Anti-cong. Anti. aggreg. therapy B-L-S + ASA, CRemarks in term of FU
1. (f)Improved, FR,
FC-I		20
(98)		428740
(+1.4)		48MVP-9/-9
30/45		B-L-S + ASA + C
++		RPA-PFR
exchange
4 mo. after ePAB
2. (f)Improved
FR
FC-I		6.5
(55)		711227
(+1.5)		57MVP-9/-7
30/32		B-L-S + ASA + C6 mo FU Infect/RPA thrombus?
RPA-PFR
partial-de-banding
3. (m)Improved
FR
FC-I		4.5
(30)		411824
(+1.5)		55MVP-7/-7
32/36		B-L-S + ASA + CBarth-S.
related intermittent
diarrhea

Abbreviations: Anti-cong., congestive; Anti-aggreg., aggregative; ASA, acetyl-salicylic-acid; B, bisoprolol; BW, body weight; C, clopidogrel; CV, controlled ventilation; DCM, dilated cardiomyopathy; EDD, enddiastolic diameter; EF, ejection fraction; ePAB, endo-pulmonary artery banding; FC, functional class; FC-I, functional class I; FR, functional Ross-class; FU, follow-up; HR, heart rate; L, lisinopril; Le, levosimendan; LPA, left pulmonary artery; LV, left ventricle; M, milrinone; mo., months; MVP, Medtronic® Vascular Plug; pts, patients; PFR, pulmonary flow restrictor; RPA, right pulmonary artery; S, spironolactone; -S., syndrome.

Table 2
Open in new tab

Patient data during follow-up (see also text)

LV-DCM pts number (sex)Further diagnoses ROSS/NYHA FC (I–IV)BW (kg) (percentile)Age (mo)HR (/min) at restLV-EDD (mm) z-scoreLV-EF (%)RPA/LPA MVP-7 or -9 dP (mmHG)Anti-cong. Anti. aggreg. therapy B-L-S + ASA, CRemarks in term of FU
1. (f)Improved, FR,
FC-I		20
(98)		428740
(+1.4)		48MVP-9/-9
30/45		B-L-S + ASA + C
++		RPA-PFR
exchange
4 mo. after ePAB
2. (f)Improved
FR
FC-I		6.5
(55)		711227
(+1.5)		57MVP-9/-7
30/32		B-L-S + ASA + C6 mo FU Infect/RPA thrombus?
RPA-PFR
partial-de-banding
3. (m)Improved
FR
FC-I		4.5
(30)		411824
(+1.5)		55MVP-7/-7
32/36		B-L-S + ASA + CBarth-S.
related intermittent
diarrhea
LV-DCM pts number (sex)Further diagnoses ROSS/NYHA FC (I–IV)BW (kg) (percentile)Age (mo)HR (/min) at restLV-EDD (mm) z-scoreLV-EF (%)RPA/LPA MVP-7 or -9 dP (mmHG)Anti-cong. Anti. aggreg. therapy B-L-S + ASA, CRemarks in term of FU
1. (f)Improved, FR,
FC-I		20
(98)		428740
(+1.4)		48MVP-9/-9
30/45		B-L-S + ASA + C
++		RPA-PFR
exchange
4 mo. after ePAB
2. (f)Improved
FR
FC-I		6.5
(55)		711227
(+1.5)		57MVP-9/-7
30/32		B-L-S + ASA + C6 mo FU Infect/RPA thrombus?
RPA-PFR
partial-de-banding
3. (m)Improved
FR
FC-I		4.5
(30)		411824
(+1.5)		55MVP-7/-7
32/36		B-L-S + ASA + CBarth-S.
related intermittent
diarrhea

Abbreviations: Anti-cong., congestive; Anti-aggreg., aggregative; ASA, acetyl-salicylic-acid; B, bisoprolol; BW, body weight; C, clopidogrel; CV, controlled ventilation; DCM, dilated cardiomyopathy; EDD, enddiastolic diameter; EF, ejection fraction; ePAB, endo-pulmonary artery banding; FC, functional class; FC-I, functional class I; FR, functional Ross-class; FU, follow-up; HR, heart rate; L, lisinopril; Le, levosimendan; LPA, left pulmonary artery; LV, left ventricle; M, milrinone; mo., months; MVP, Medtronic® Vascular Plug; pts, patients; PFR, pulmonary flow restrictor; RPA, right pulmonary artery; S, spironolactone; -S., syndrome.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close